The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.

Dr Ray O’Connor takes a look at some of the most recent clinical studies on obesity – a major global health crisis ...

Since 2014, the Mexican government has taken steps to address the overweight and obesity epidemic. That year, it launched ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

A new study reveals that long-term high-fat diets reduce pleasure from eating by lowering neurotensin, a brain peptide that ...

Responding to the progress of its obesity pipeline, the Chinese biotech is stepping up its investment in metabolic disease ...

The transformation of healthy cells into invasive colorectal tumors is an extraordinarily complex process involving numerous ...

Under terms of the deal, Novo Nordisk will obtain global rights to develop, manufacture, and commercialize LX9851 for obesity ...

Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...

Learn more about whether Jazz Pharmaceuticals plc or Novo Nordisk A/S is a better investment based on AAII's A+ Investor ...

Novo has been trying to strengthen its foothold in the potential $150 billion obesity market through the ... ANALYSISFor China and US Inc, Trump's trade war feels much worse this time 4:01 AM ...